Dr Trevor Hansel

In 2009 Trevor Hansel became Medical Director of the Imperial Clinical Respiratory Research Unit (ICRRU) at St Mary's Hospital, having been Medical Director of the NHLI Clinical Studies Unit at the Royal Brompton Hospital from 1997-2009. He is also an Honorary Consultant at St. Mary's Hospital in London.

He obtained his medical degree in 1982 at the Welsh National School of Medicine, Cardiff and then completed higher specialist medical training in clinical immunology in Birmingham. From 1990-1993 Trevor then performed clinical asthma research in Davos, Switzerland; developing methods for blood eosinophil isolation and sputum eosinophil surface marker assessment. Following this, he worked in respiratory drug development with Sandoz and Roche in Basel; working in project management and clinical development. In addition, he has regulatory experience from the Biotechnology Unit of the Medicines Control Agency (MCA) in London.

Trevor has a specialist interest in phase II clinical testing of new anti-inflammatory therapies for asthma and COPD, and has worked on a large study on the effects of smoking cessation. Novel methods have been developed for nasal allergen challenge, human whole blood flow cytometry to demonstrate pharmacodynamic activity of anti-inflammatory drugs, and to measure cytokines and chemokines in induced sputum and bronchial and nasal lining fluid.

Trevor Hansel and Peter Barnes are authors of "An Atlas of COPD" (Parthenon, 2004) and also together edited "New Drugs for Asthma, Allergy and COPD" (Karger, 2001) and edit the Respiratory Medicine section of the Prous Science TTMed website. In addition, Trevor is currently editing Thomson Reuters: New Drugs and Targets for Respiratory Diseases, that will be available in September 2010.